glp 1 and kidney cancer Glucagon-like Peptide-1 Receptor Agonists Diabetic Disease: From Bench to Bed-Side GLP-1s tied to similar kidney

Do I have to reach 15 mg

The drug itself is not what creates eligibility

Clinical signs of systemic immune-mediated side-effects usually become manifest only during advanced clinical development of drugs

Historically, the obesity pharmacotherapy literature notes early trial signals and also that development was terminated after failure to show meaningful weight loss in a larger, longer trial (as summarized in a peer-reviewed review discussing a 12-week signal and a later 24-week negative result)

Surg Obes Relat Dis 14(3):264269 Meneses E, Zagales I, Fanfan D, Zagales R, McKenney M, Elkbuli A (2021) Surgical, metabolic, and prognostic outcomes for Roux-en-Y gastric bypass versus sleeve gastrectomy: a systematic review